Multiplex Microsphere Immunoassay Identifies Three Flavivirus Infections
|
By LabMedica International staff writers Posted on 19 Sep 2019 |

Image: The MagPlex Multiplexing Microspheres (Photo courtesy of Luminex).
The explosive spread of Zika virus (ZIKV) and associated complications in flavivirus-endemic regions underscore the need for sensitive and specific serodiagnostic tests to distinguish ZIKV, dengue virus (DENV) and other flavivirus infections.
ZIKV is a member of the genus Flavivirus of the family Flaviviridae, which includes several pathogenic mosquito-borne viruses in different serocomplexes. The four serotypes of dengue virus (DENV) belong to the DENV serocomplex; West Nile virus (WNV) and Japanese encephalitis virus (JEV) to the JEV serocomplex; yellow fever virus (YFV) as a single member; and ZIKV.
Tropical medicine specialists at the University of Hawaii at Manoa, (Honolulu, HI, USA) and their colleagues developed a high-throughput and multiplex IgG microsphere immunoassay (MIA) using the NS1 proteins of DENV1-DENV4, ZIKV and West Nile virus (WNV) to test samples from reverse-transcription-polymerase-chain reaction-confirmed cases, including primary DENV1, DENV2, DENV3, WNV and ZIKV infections, secondary DENV infection, and ZIKV infection with previous DENV infection.
The NS1 gene (corresponding to amino acid residues 1–352) of ZIKV (HPF2013 strain) with a His-tag at the C-terminus was codon-optimized. Six purified NS1 proteins, bovine serum albumin (BSA) and PBS (as negative antigen control) were coupled individually onto eight types of magnetic carboxylated microsphere beads containing different fluorophores (MagPlexTM-C) using two-step carbodiimide process at room temperature. Microsphere immunoassays (MIA) were performed and read by a Luminex 200 machine. Enzyme-linked immunosorbent assays were performed for DENV1-, DENV2-, DENV3-, and ZIKV-NS1 IgG.
The scientists reported that a combination of four DENV NS1 IgG MIAs revealed a sensitivity of 94.3% and specificity of 97.2% to detect DENV infection. The ZIKV and WNV NS1 IgG MIAs had a sensitivity/specificity of 100%/87.9% and 86.1%/78.4%, respectively. A positive correlation was found between the readouts of ELISA and MIA for the different NS1 tested. Based on the ratio of relative median fluorescence intensity of ZIKV NS1 to DENV1 NS1, the IgG MIA can distinguish ZIKV infection with previous DENV infection and secondary DENV infection with a sensitivity of 88.9%–90.0% and specificity of 91.7%–100.0%.
The authors concluded that the multiplex and high-throughput assay could be applied to serodiagnosis and serosurveillance of DENV, ZIKV and WNV infections in endemic regions. The study was published on August 23, 2019, in the journal PLOS Neglected Tropical Diseases.
Related Links:
University of Hawaii at Manoa
ZIKV is a member of the genus Flavivirus of the family Flaviviridae, which includes several pathogenic mosquito-borne viruses in different serocomplexes. The four serotypes of dengue virus (DENV) belong to the DENV serocomplex; West Nile virus (WNV) and Japanese encephalitis virus (JEV) to the JEV serocomplex; yellow fever virus (YFV) as a single member; and ZIKV.
Tropical medicine specialists at the University of Hawaii at Manoa, (Honolulu, HI, USA) and their colleagues developed a high-throughput and multiplex IgG microsphere immunoassay (MIA) using the NS1 proteins of DENV1-DENV4, ZIKV and West Nile virus (WNV) to test samples from reverse-transcription-polymerase-chain reaction-confirmed cases, including primary DENV1, DENV2, DENV3, WNV and ZIKV infections, secondary DENV infection, and ZIKV infection with previous DENV infection.
The NS1 gene (corresponding to amino acid residues 1–352) of ZIKV (HPF2013 strain) with a His-tag at the C-terminus was codon-optimized. Six purified NS1 proteins, bovine serum albumin (BSA) and PBS (as negative antigen control) were coupled individually onto eight types of magnetic carboxylated microsphere beads containing different fluorophores (MagPlexTM-C) using two-step carbodiimide process at room temperature. Microsphere immunoassays (MIA) were performed and read by a Luminex 200 machine. Enzyme-linked immunosorbent assays were performed for DENV1-, DENV2-, DENV3-, and ZIKV-NS1 IgG.
The scientists reported that a combination of four DENV NS1 IgG MIAs revealed a sensitivity of 94.3% and specificity of 97.2% to detect DENV infection. The ZIKV and WNV NS1 IgG MIAs had a sensitivity/specificity of 100%/87.9% and 86.1%/78.4%, respectively. A positive correlation was found between the readouts of ELISA and MIA for the different NS1 tested. Based on the ratio of relative median fluorescence intensity of ZIKV NS1 to DENV1 NS1, the IgG MIA can distinguish ZIKV infection with previous DENV infection and secondary DENV infection with a sensitivity of 88.9%–90.0% and specificity of 91.7%–100.0%.
The authors concluded that the multiplex and high-throughput assay could be applied to serodiagnosis and serosurveillance of DENV, ZIKV and WNV infections in endemic regions. The study was published on August 23, 2019, in the journal PLOS Neglected Tropical Diseases.
Related Links:
University of Hawaii at Manoa
Latest Immunology News
- Antibody Profiles Provide Clues to Long COVID Severity and Symptoms
- Aptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
- Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
- Study Points to Autoimmune Pathway Behind Long COVID Symptoms
- Immune Enzyme Linked to Treatment-Resistant Inflammatory Bowel Disease
- Simple Blood Test Could Replace Biopsies for Lung Transplant Rejection Monitoring
- Routine TB Screening Test May Reveal Immune Aging and Mortality Risk
- Biomarkers and Molecular Testing Advance Precision Allergy Care
- Point-of-Care Tests Could Expand Access to Mpox Diagnosis
- T-Cell Senescence Profiling May Predict CAR T Responses
- Finger-Prick Lateral Flow Test Detects Sepsis Biomarkers at Point of Care
- Study Highlights Low Sensitivity of Current Lyme Tests in Early Infection
- Immune Aging Clock Quantifies Immunosenescence and Identifies Therapeutic Target
- Study Finds Influenza Often Undiagnosed in Winter Deaths
- Combined Screening Approach Identifies Early Leprosy Cases
- Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Channels
Clinical Chemistry
view channel
Simple Oral Swab Monitors Persistent Inflammation in Primary Ciliary Dyskinesia
Primary ciliary dyskinesia is a rare lung disease that affects about one in 7,500 to 10,000 live births worldwide. Symptoms can begin in the newborn period and progress to recurrent respiratory infections... Read more
Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features
Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read moreMolecular Diagnostics
view channel
Long-Read DNA Test Improves Diagnosis of Rare Genetic Diseases
Rare diseases affect up to 400 million people worldwide, yet many remain difficult to diagnose and often require years-long diagnostic journeys. Approximately 80% have a genetic basis, but conventional... Read more
At-Home Urine Collection Kit Enables High-Throughput STI Screening
Sexually transmitted infection screening often hinges on access to private, convenient sample collection and timely laboratory processing. Many patients face logistical or privacy barriers that limit participation... Read more
Noninvasive Sequencing Test Approaches Invasive Genome Sequencing for Prenatal Screening
Prenatal genetic evaluation guides obstetric care, but standard diagnostics often require invasive procedures that carry risks, stress, and access barriers. Noninvasive prenatal testing (NIPT) has expanded... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Antibody Profiles Provide Clues to Long COVID Severity and Symptoms
Persistent symptoms after acute COVID-19 affect millions of people, causing fatigue, respiratory issues, and cognitive deficits that can be difficult to quantify with standard tests. Clinical teams lack... Read moreAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read morePathology
view channel
New Companion Diagnostic Expands Precision Medicine in Prostate Cancer
Prostate cancer is a leading cancer diagnosis in men and becomes particularly aggressive when it presents as metastatic, hormone-sensitive disease. Tumors with loss of phosphatase and tensin homolog (PTEN)... Read more
Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer
Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
AI Tool Speeds Brain Tumor Classification from Routine Histology Slides
Accurate classification of brain and spinal cord tumors increasingly depends on molecular profiling alongside histology, but access to such testing remains limited and results can take about two weeks.... Read more
IHC Companion Diagnostic Standardizes Mismatch Repair Testing for Cancer Immunotherapy
Deficient DNA mismatch repair is an established predictive biomarker for response to immune checkpoint inhibitors, yet access to standardized assessment has varied across tumor types. Cancer remains the... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Open-Source Consortium Aims to Standardize Digital Pathology Workflows
Digital pathology is expanding rapidly as laboratories adopt whole-slide imaging and computational tools to meet growing diagnostic and biomarker-testing demand. However, fragmented software infrastructure... Read more








